文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒抗菌药物管理

结核病的治疗:药物、耐药与药效学

The Treatment of Tuberculosis.
PubMed 文献 · Clin Pharmacol Ther · 2021-06-05

结核病仍是全球感染性死亡的主要原因,贫困是重要驱动因素。结核病分为潜伏性和活动性,治疗不同。一线药物异烟肼早期杀菌活性强,利福平灭菌活性强,吡嗪酰胺和乙胺丁醇各有特定作用。耐药结核需使用再利用药物和新药,需避免不良反应重叠。药效学可用AUC/MIC描述,空心纤维感染模型和动物模型有助于筛选短程高效方案,治疗药物监测和剂量个体化可优化患者药物暴露。

要点

  • 异烟肼早期杀菌活性强,利福平灭菌活性强,两者在一线方案中作用不同。
  • 耐药结核治疗可选用莫西沙星、左氧氟沙星、利奈唑胺、氯法齐明、β-内酰胺类等再利用药物及贝达喹啉、普托马尼、德拉马尼等新药。
  • 选择耐药结核药物时需避免不良反应谱重叠,QTc间期延长是目前可管理的关注点。

核心结论

  • 结核病治疗需区分潜伏性和活动性,一线药物各有特定作用,耐药结核需合理选择再利用药物和新药以避免不良反应重叠。
  • 药效学可用AUC/MIC描述,通过治疗药物监测和剂量个体化优化药物暴露可改善治疗。

主要发现

  • 异烟肼早期杀菌活性优秀,利福平灭菌活性优秀,吡嗪酰胺和乙胺丁醇完成药物敏感结核的一线方案。
  • 耐药结核日益受关注,部分通过再利用药物(莫西沙星、左氧氟沙星、利奈唑胺、氯法齐明、β-内酰胺类)和新药(贝达喹啉、普托马尼、德拉马尼)应对。
  • QTc间期延长是需关注的不良反应,但迄今可管理。
  • 药物进入中枢神经系统、骨骼和肺结核空洞等避难所仍是重要挑战。
  • 大多数结核药物的药效学可用AUC/MIC描述。

临床怎么用

  • 临床选择结核药物时需避免不良反应谱重叠,尤其关注QTc间期延长。
  • 可利用治疗药物监测和剂量个体化优化每位患者的药物暴露。
  • 空心纤维感染模型和动物模型(小鼠、猕猴)可加速筛选高效短程方案,甚至用于极端耐药结核。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a major driver. Clinically, TB presents as "latent" TB and active TB disease, and the treatment for each is different. TB drugs can display "early bactericidal activity (EBA)" and / or "sterilizing activity" (clearing persisters). Isoniazid is excellent at the former, and rifampin is excellent at the latter. Pyrazinamide and ethambutol complete the first-line regimen for drug-susceptible TB, each playing a specific role. Drug-resistant TB is an increasing concern, being met, in part, with repurposed drugs (including moxifloxacin, levofloxacin, linezolid, clofazimine, and beta-lactams) and new drugs (including bedaquiline, pretomanid, and delamanid). One challenge is to select drugs without overlapping adverse drug reaction profiles. QTc interval prolongation is one such concern, but to date, it has been manageable. Drug penetration into organism sanctuaries, such as the central nervous system, bone, and pulmonary TB cavities remain important challenges. The pharmacodynamics of most TB drugs can be described by the area under the curve (AUC) divided by the minimal inhibitory concentration (MIC). The hollow fiber infection model (HFIM) and various animal models (especially mouse and macaque) allow for sophisticated pharmacokinetic/pharmacodynamic experiments. These experiments may hasten the selection of the most potent, shortest possible regimens to treat even extremely drug resistant TB. These findings can be translated to humans by optimizing drug exposure in each patient, using therapeutic drug monitoring and dose individualization.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Peloquin CA, Davies GR. The Treatment of Tuberculosis. Clin Pharmacol Ther. 2021. PMID: 33837535. doi:10.1002/cpt.2261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。